Drugs News and Research

RSS

Researchers develop a class of compounds that may help eradicate Chagas disease

A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.

27 Dec 2013

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells-macrophages-are stimulated in response to pathogens.

27 Dec 2013

Activation of protein P300 plays central role in DNA repair in hippocampal neurons

Various medications have been developed to treat neurodegenerative disorders, and drugs without significant side effects are gaining widespread interest such disorders.

27 Dec 2013

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering.

26 Dec 2013

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, announced today that its investor group and employee shareholders have reached a definitive agreement to sell the Commercial Business to Madison Dearborn Partners in a transaction valued at approximately $1.6 billion.

26 Dec 2013

Genetics of rheumatoid arthritis contributes to biology and drug discovery

The results of the largest international study to date into the genetic basis of rheumatoid arthritis shed light on the biology of the disease and provide evidence that large-scale genetic studies can assist in the identification of new drugs for complex disorders such as rheumatoid arthritis.

26 Dec 2013

Researchers uncover new genetic clue that contributes to increased risk of type 2 diabetes

An international team of researchers in Mexico and the United States has uncovered a new genetic clue that contributes to an increased risk of developing type 2 diabetes, particularly the elevated risk among Mexican and other Latin American populations.

26 Dec 2013

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain.

25 Dec 2013

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food & Drug Administration has extended the Prescription Drug User Fee Act Priority Review action date for the ulcerative colitis indication of Takeda's investigational biologic, vedolizumab.

24 Dec 2013

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

U.S. FDA grants Veloxis Orphan Drug status for Envarsus

Veloxis Pharmaceuticals A/S, today announced that Envarsus was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants.

24 Dec 2013

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.

24 Dec 2013

Rutgers New Jersey Medical School's David Perlin explains how fungal infections can become deadly

Ask someone what the term 'fungus' brings to mind, and chances are it will be an image of something that smells or looks disgusting. Ask David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, and the response will be far more somber - because he knows how deadly fungi can be.

24 Dec 2013

Changes to LZTR1 gene predispose people to develop schwannomas

Changes to a gene called LZTR1 predispose people to develop a rare disorder where multiple tumors called schwannomas form near nerve pathways, according to a study published today in the journal Nature Genetics and led by researchers from the University of Alabama at Birmingham.

24 Dec 2013

Acupuncture treatments may help alleviate side effects of breast cancer drugs

A new analysis has found that both real and sham acupuncture treatments may help alleviate side effects of drugs commonly used to treat breast cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help clinicians improve care for cancer patients. The results also raise the question of whether sham acupuncture is truly inert or may, like real acupuncture, have beneficial effects.

24 Dec 2013

Genetic screening identifies genes driving resistance with guide RNA library

Researchers have developed a method to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types.

23 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

23 Dec 2013

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Both real and sham weekly acupuncture treatments eased hot flashes and other side effects of anticancer drug treatment in a small, preliminary study of breast cancer patients, Baltimore researchers have found.

23 Dec 2013

Drugs News and Research

Researchers develop a class of compounds that may help eradicate Chagas disease

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Activation of protein P300 plays central role in DNA repair in hippocampal neurons

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Genetics of rheumatoid arthritis contributes to biology and drug discovery

Researchers uncover new genetic clue that contributes to increased risk of type 2 diabetes

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Concordia Healthcare acquires Pinnacle Biologics

U.S. FDA grants Veloxis Orphan Drug status for Envarsus

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Rutgers New Jersey Medical School's David Perlin explains how fungal infections can become deadly

Changes to LZTR1 gene predispose people to develop schwannomas

Acupuncture treatments may help alleviate side effects of breast cancer drugs

Genetic screening identifies genes driving resistance with guide RNA library

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News